An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NOTE: Currently, this study is only open to nivolumab+daratumumab vs daratumumab monotherapy
in multiple myeloma patients.

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Have received at least 3 prior lines of therapy, including a proteasome inhibitor [PI]
and an immunomodulatory agent [IMiD] OR have disease that is double refractory to a PI
and IMiD

- More than 12 weeks post-transplant of your own blood forming stem cells (autologous
transplant)

- Have detectable disease measured by a specific protein in your blood and/or urine

- Must consent to bone marrow aspirate or biopsy.

Exclusion Criteria:

- Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell
dyscrasia, or monoclonal gammopathy of undetermined significance (MGUS), smoldering
multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, POEMS
syndrome or active plasma cell leukemia

- Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or
anti-CD38 antibody, or allogeneic stem cell transplantation

- Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen or
Hepatitis C antibody positive (except if HCV-RNA negative), or history of active
chronic hepatitis B or C

- History of central nervous system involvement or symptoms suggestive of central
nervous system involvement by multiple myeloma

Other protocol defined inclusion/exclusion criteria could apply